Remove DNA Remove Immune Response Remove Medicine Remove RNA
article thumbnail

Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class

pharmaphorum

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98
article thumbnail

World RNA Day: What impact RNA it had on drug discovery?  

Drug Discovery World

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”. The evolving field of genomic medicine. There are two components to genomic medicine, known as the payload and the vector.

Genome 92
article thumbnail

Predictive diagnostics: closing the precision medicine gap

Drug Discovery World

Precision medicine promises a paradigm shift to confidently match the right patients to the right treatment at the right time. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. In pursuit of this, the number of new therapeutics in development has boomed.

article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. This response was also seen in the RV 144 trial, she notes.

article thumbnail

A vaccine for the ‘previously undruggable’ is just a decade away 

Drug Discovery World

Personalised vaccines mRNA-4157/V940 is a novel investigational mRNA-based personalised cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neo-antigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumour.

article thumbnail

Personalised mRNA cancer vaccine prolongs survival in melanoma

Drug Discovery World

“Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.